UBS: Lowered target price for Hutchison China MediTech (00013.HK) to 36.9 Hong Kong dollars, rating it as "buy".

According to Zhixun Finance APP, UBS released a research report stating that Hutchison Chi-Med (00013.HK) has lowered its revenue guidance for oncology drugs this year to $270 million to $350 million. The bank said it will lower the company's revenue forecast for 2025 to 2027, with the H-share target price lowered from HK$37.7 to HK$36.9, and maintains its rating as "buy".